Philadelphia chromosome-positive acute myeloid leukemia (Ph+-AML) has a poor response to anthracycline- and cytarabine-containing regimens, high relapse rate, and dismal prognosis.

This information was originally presented on September 21, 2013, at the NCCN 8^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia (AML) and discuss the clinical evidence that support the recommendations.

This recorded webinar is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Acute Myeloid Leukemia (AML).

This webinar is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Acute Myeloid Leukemia (AML).

The Westin Diplomat
Hollywood, Florida

Vaccination is an important strategy for preventing infections in patients with hematologic malignancies. Hematopoietic cell transplant (HCT) recipients have diminished immunity against vaccine-preventable diseases after transplantation.

The second part of the 2012 NCCN Case Manager and Medical Director Program™ webinar series is on the topics of metastatic melanoma, acute myeloid leukemia, cancer survivorship, and techniques for telephonic case managers.

Predicting the outcome of therapy in patients with acute myeloid leukemia (AML) is currently necessary for making treatment decisions.

The molecular analysis of biomarkers in oncology is rapidly advancing, but the incorporation of new molecular tests into clinical practice will require a greater understanding of the genetic changes that drive malignancy, the assays used to measure the resulting phenotypes and genotypes, and the